News

Sinopia Biosciences selects SB-0110 for Phase 1 Parkinson’s trial

Sinopia Biosciences has selected SB-0110 as its lead clinical candidate for Parkinson’s disease after extensive preclinical studies. The move has triggered a cumulative funding of $3.3 million of its fast-track Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke. The fast-track SBIR…

First healthy volunteer dosed in study of HER-096 for Parkinson’s

The first healthy volunteer has been dosed in a clinical study that will test the safety and efficacy of Herantis Pharma’s HER-096 treatment candidate for Parkinson’s disease, the company announced in a press release. The Phase 1a clinical trial also is evaluating the ability of HER-096 to penetrate…

Anti-nausea meds not necessary when starting Kynmobi

Medications to prevent nausea and vomiting usually are not necessary for Parkinson’s disease patients beginning treatment with Kynmobi (apomorphine hydrochloride), according to a recent analysis of Phase 3 clinical trial data. Nearly 90% of patients who did not use these medications were still able to achieve an optimal…

Parkinson’s disease progression may be influenced by immune B-cells

Greater proportions of immune regulatory B-cells were associated with better motor performance in people with early Parkinson’s disease, a study revealed. Regulatory B-cell subsets may be protective by limiting pro-inflammatory responses that contribute to disease progression, data showed. Meanwhile, elevated levels of antibodies produced by regular B-cells against the…

Smartphones and smartwatches may help track Parkinson’s in trials: Study

Remote assessments using smartphones and smartwatches could be used in clinical trials to track the severity of Parkinson’s disease, a new study indicates. “In this multicenter study, a commercially available smartwatch and a smartphone research application captured key motor and non-motor features of early, untreated” Parkinson’s, the researchers wrote,…